First Time Loading...

Veracyte Inc
NASDAQ:VCYT

Watchlist Manager
Veracyte Inc Logo
Veracyte Inc
NASDAQ:VCYT
Watchlist
Price: 19.2 USD 1.8% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. [ Read More ]

The intrinsic value of one VCYT stock under the Base Case scenario is 15.08 USD. Compared to the current market price of 19.2 USD, Veracyte Inc is Overvalued by 21%.

Key Points:
VCYT Intrinsic Value
Base Case
15.08 USD
Overvaluation 21%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Veracyte Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling VCYT stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Veracyte Inc

Provide an overview of the primary business activities
of Veracyte Inc.

What unique competitive advantages
does Veracyte Inc hold over its rivals?

What risks and challenges
does Veracyte Inc face in the near future?

Has there been any significant insider trading activity
in Veracyte Inc recently?

Summarize the latest earnings call
of Veracyte Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Veracyte Inc.

Provide P/S
for Veracyte Inc.

Provide P/E
for Veracyte Inc.

Provide P/OCF
for Veracyte Inc.

Provide P/FCFE
for Veracyte Inc.

Provide P/B
for Veracyte Inc.

Provide EV/S
for Veracyte Inc.

Provide EV/GP
for Veracyte Inc.

Provide EV/EBITDA
for Veracyte Inc.

Provide EV/EBIT
for Veracyte Inc.

Provide EV/OCF
for Veracyte Inc.

Provide EV/FCFF
for Veracyte Inc.

Provide EV/IC
for Veracyte Inc.

Show me price targets
for Veracyte Inc made by professional analysts.

What are the Revenue projections
for Veracyte Inc?

How accurate were the past Revenue estimates
for Veracyte Inc?

What are the Net Income projections
for Veracyte Inc?

How accurate were the past Net Income estimates
for Veracyte Inc?

What are the EPS projections
for Veracyte Inc?

How accurate were the past EPS estimates
for Veracyte Inc?

What are the EBIT projections
for Veracyte Inc?

How accurate were the past EBIT estimates
for Veracyte Inc?

Compare the revenue forecasts
for Veracyte Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Veracyte Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Veracyte Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Veracyte Inc compared to its peers.

Compare the P/E ratios
of Veracyte Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Veracyte Inc with its peers.

Analyze the financial leverage
of Veracyte Inc compared to its main competitors.

Show all profitability ratios
for Veracyte Inc.

Provide ROE
for Veracyte Inc.

Provide ROA
for Veracyte Inc.

Provide ROIC
for Veracyte Inc.

Provide ROCE
for Veracyte Inc.

Provide Gross Margin
for Veracyte Inc.

Provide Operating Margin
for Veracyte Inc.

Provide Net Margin
for Veracyte Inc.

Provide FCF Margin
for Veracyte Inc.

Show all solvency ratios
for Veracyte Inc.

Provide D/E Ratio
for Veracyte Inc.

Provide D/A Ratio
for Veracyte Inc.

Provide Interest Coverage Ratio
for Veracyte Inc.

Provide Altman Z-Score Ratio
for Veracyte Inc.

Provide Quick Ratio
for Veracyte Inc.

Provide Current Ratio
for Veracyte Inc.

Provide Cash Ratio
for Veracyte Inc.

What is the historical Revenue growth
over the last 5 years for Veracyte Inc?

What is the historical Net Income growth
over the last 5 years for Veracyte Inc?

What is the current Free Cash Flow
of Veracyte Inc?

Financials

Balance Sheet Decomposition
Veracyte Inc

Current Assets 285.6m
Cash & Short-Term Investments 216.5m
Receivables 40.4m
Other Current Assets 28.8m
Non-Current Assets 829.3m
PP&E 30.9m
Intangibles 791.6m
Other Non-Current Assets 6.8m
Current Liabilities 61.2m
Accounts Payable 12.9m
Accrued Liabilities 43.5m
Other Current Liabilities 4.8m
Non-Current Liabilities 9.6m
Other Non-Current Liabilities 9.6m
Efficiency

Earnings Waterfall
Veracyte Inc

Revenue
361.1m USD
Cost of Revenue
-112.9m USD
Gross Profit
248.1m USD
Operating Expenses
-265.6m USD
Operating Income
-17.4m USD
Other Expenses
-57m USD
Net Income
-74.4m USD

Free Cash Flow Analysis
Veracyte Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

VCYT Profitability Score
Profitability Due Diligence

Veracyte Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
Positive Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
40/100
Profitability
Score

Veracyte Inc's profitability score is 40/100. The higher the profitability score, the more profitable the company is.

VCYT Solvency Score
Solvency Due Diligence

Veracyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Veracyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VCYT Price Targets Summary
Veracyte Inc

Wall Street analysts forecast VCYT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VCYT is 31.45 USD with a low forecast of 21.21 USD and a high forecast of 38.85 USD.

Lowest
Price Target
21.21 USD
10% Upside
Average
Price Target
31.45 USD
64% Upside
Highest
Price Target
38.85 USD
102% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

VCYT Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

VCYT Price
Veracyte Inc

1M 1M
-11%
6M 6M
-8%
1Y 1Y
-17%
3Y 3Y
-58%
5Y 5Y
-17%
10Y 10Y
+47%
Annual Price Range
19.2
52w Low
18.86
52w High
29.92
Price Metrics
Average Annual Return 8.67%
Standard Deviation of Annual Returns 50.21%
Max Drawdown -81%
Shares Statistics
Market Capitalization 1.5B USD
Shares Outstanding 78 440 000
Percentage of Shares Shorted 5.48%

VCYT Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Veracyte Inc Logo
Veracyte Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.5B USD

Dividend Yield

0%

Description

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 761 full-time employees. The company went IPO on 2013-10-30. The firm offers customized biomarker testing and analytical services. The company offers a complete range of in vitro diagnostic (IVD) and companion diagnostic development services to biopharmaceutical companies and diagnostic companies. The company offers tests across various diseases, which include Afirma Genomic Sequencing Classifier for thyroid cancer; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer; Prosigna Breast Cancer Assay for breast cancer; Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer; Envisia Genomic Classifier test for interstitial lung diseases; Decipher Bladder Genomic Classifier test for bladder cancer and Immunoscore Colon Cancer Test for colon cancer. The company also offers Immunogram, a spatial molecular analysis and bioinformatics tool that integrates genomic, transcriptomic and proteomic data to help researchers understand the intricacies of the tumor immune microenvironment.

Contact

CALIFORNIA
South San Francisco
6000 Shoreline Ct Ste 300
+16502436300.0
https://www.veracyte.com/

IPO

2013-10-30

Employees

761

Officers

CEO & Director
Mr. Marc A. Stapley
Executive VP & CFO
Ms. Rebecca Chambers
Executive VP, General Counsel & Chief People Officer
Ms. Annie McGuire
VP & Chief Accounting Officer
Mr. Jonathan Wygant
Senior VP & Chief Information Officer
Mr. Steven French
Chief Scientific & Medical Officer
Dr. Phillip G. Febbo M.D.
Show More
Senior Vice President of Corporate Marketing, Communications & Commercial Operations
Ms. Karen Possemato
Executive VP & Chief Business Officer
Mr. Robert Brainin
Chief Commercial Officer for CLIA Business
Dr. John Leite Ph.D.
Senior Vice President
Ms. Corinne Danan
Show Less

See Also

Discover More
What is the Intrinsic Value of one VCYT stock?

The intrinsic value of one VCYT stock under the Base Case scenario is 15.08 USD.

Is VCYT stock undervalued or overvalued?

Compared to the current market price of 19.2 USD, Veracyte Inc is Overvalued by 21%.